evidencegaps
Primary study · included by 1 review

Evaluation of ELISA testing for BP180 and BP230 as a diagnostic modality for bullous pemphigoid: a clinical experience.

Keller 2016 · Keller Jesse J, Kittridge Ashley L, Debanne Sara M, et al. · Archives of dermatological research · 2016

Included by

Diagnostic Agreement in Subepidermal Blistering Diseases: Is ELISA Test Reliable as Direct Immunofluorescence? A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.
Non-Cochrane · DTA · 2026 · cited as Keller 2016 · Table 2; References
Outcome this study informsPooled effectEvidenceCertainty
Diagnostic agreement between ELISA and DIF (risk difference in test positivity)
ELISA (BP180 and/or BP230) in bullous pemphigoid (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy
RD 0.19 [0.13, 0.25]27 studies · 2238 participantsGRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity)
ELISA for BP180 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy
RD 0.26 [0.19, 0.33]35 studies · 2776 participantsGRADE not reported
Diagnostic agreement between ELISA and DIF (risk difference in test positivity)
ELISA for BP230 autoantibodies (index test) vs Direct immunofluorescence (DIF, reference standard) · At first diagnosis, before immunosuppressive therapy
RD 0.59 [0.47, 0.71]27 studies · 2097 participantsGRADE not reported

1 including review in total.